Canadian Nanomedicine Expertise Database – NMIN – Nanomedicines Innovation Network

As part of its legacy, the NanoMedicines Innovation Network (NMIN) developed this online database of Canadian nanomedicine researchers and the areas of expertise represented within their labs. The database is intended as a tool to facilitate collaboration among nanomedicine researchers and labs—within and beyond the NMIN Network, now and in the future.

The database can be searched by keyword in any or all fields.

If you are an established Canadian professional with expertise related to nanomedicine research and/or innovation, please take ~5 minutes to complete this brief survey and be included in this database.

All	Institution	Researcher	Nanodelivery type	Targeting approach	Application	Disease model	Protocols	Instrumentation	Auxilliary expertise
Researcher: Mohsen Akbari Institution: University of Victoria Nanodelivery type Polymer-based Targeting approach Physical targeting: pH sensitive; Temperature sensitive; Light sensitive Application Drug delivery: Soluble molecules; Insoluble molecules Disease model(s) Cancer (In vitro, Organoid, Primary cells) Other: wound healing (In vitro, Organoid, In vivo: Mouse and pig models) Protocols: Microfluidics	University of Victoria	Mohsen Akbari	Polymer-based	Physical targeting pH sensitive Temperature sensitive Light sensitive	Drug delivery Soluble molecules Insoluble molecules	Cancer Other Wound healing In vitro Organoid In vivo Mouse and pig models In vitro Organoid Primary cells	Microfluidics
Researcher: Russ Algar Institution: University of British Columbia Nanodelivery type Polymer-based Inorganic Targeting approach Active targeting: Antibody or antibody fragments; Peptide; Aptamer Application Nano-imaging: Diagnostics; Fluorescent imaging Other: Biosensors, Assays, Molecular Diagnostics Disease model(s) Cancer (In vitro) Heart failure (In vitro) Protocols: Microfluidics; Other (3D printing, device development, nanoparticle surface chemistry and bioconjugation; suite of steady-state and time-resolved optical spectroscopies; nanoparticle tracking analysis; single-molecule/particle fluorescence imaging)	University of British Columbia	Russ Algar	Polymer-based Inorganic	Active targeting: Antibody or antibody fragments, Peptide, Aptamer	Nano-imaging: Diagnostics Fluorescent imaging Other: Biosensors, Assays, Molecular Diagnostics	Cancer In vitro Heart failure In vitro	Microfluidics Other: 3D printing, device development, nanoparticle surface chemistry and bioconjugation Suite of steady-state and time-resolved optical spectroscopies, nanoparticle tracking analysis, single-molecule/particle fluorescence imaging
Researcher: Theresa M Allen Institution: University of Alberta / University of British Columbia (UBC) Nanodelivery type Lipid-based Polymer-based Targeting approach Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: mRNA/samRNA; ASO Peptide/protein delivery Disease model(s) Cancer (In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Protocols: Safety/pharmacology	University of Alberta / University of British Columbia (UBC)	Theresa M Allen	Lipid-based Polymer-based	Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive	Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: mRNA/samRNA; ASO Peptide/protein delivery	Cancer (In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model)	Safety/pharmacology
Researcher: Ildiko Badea Institution: University of Saskatchewan Nanodelivery type Lipid-based Inorganic Targeting approach Physical targeting: pH sensitive Application Drug delivery Gene delivery: DNA, siRNA Peptide/protein delivery Disease model(s) Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model) Instrumentation: Synchrotron techniques Auxiliary expertise: Other: Human research ethics	University of Saskatchewan	Ildiko Badea	Lipid-based Inorganic	Physical targeting: pH sensitive	Drug delivery Gene delivery: DNA, siRNA Peptide/protein delivery	Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model)		Synchrotron techniques	Other: Human research ethics
Researcher: Marcel Bally Institution: BC Cancer Research Centre; University of British Columbia Nanodelivery type Lipid-based Other: peptide/protein Targeting approach Active targeting: Antibody or antibody fragments; Peptide Application Drug delivery: Soluble molecules; Insoluble molecules Disease model(s) Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo PDX model, In vivo syngeneic model, In vivo metastatic model, Primary cells, Human) Infectious diseases: viral infections – BioSafety Level 2, BioSafety Level 3, In vitro (cells), In vivo (rodent) Other: neurodegenerative diseases (In vitro, Organoid, In vivo: Alzheimer’s mice, lung injury models) Protocols: Safety/pharmacology (Pre-GLP toxicity, GLP testing); Microfluidics; Pre-GMP & GMP manufacturing Instrumentation: Everything needed for formulation characterization except cryo EM Auxiliary expertise: Non-nano delivery systems; Regulatory science	BC Cancer Research Centre; University of British Columbia	Marcel Bally	Lipid-based Other peptide/protein	Active targeting Antibody or antibody fragments Peptide	Drug delivery Soluble molecules Insoluble molecules	Cancer Infectious diseases Viral infections In vitro In vivo xenograft model In vivo orthotopic model In vivo PDX model In vivo syngeneic model In vivo metastatic model Primary cells Human BioSafety Level 2 BioSafety Level 3 In vitro (cells) In vivo (rodent)	Safety/pharmacology Microfluidics Pre-GMP & GMP manufacturing Pre-GLP toxicity GLP testing	Everything needed for formulation characterization except cryo EM	Regulatory science Non-nano delivery systems
Researcher: Louis-Philippe Bernier Institution: University of British Columbia Nanodelivery type Lipid-based Targeting approach Physical targeting: pH sensitive Application Gene delivery: mRNA/samRNA Disease model(s) Other: Neurological diseases; in vivo (rodent models) Protocols: Safety/pharmacology (Pre-GLP toxicity)	University of British Columbia	Louis-Philippe Bernier	lipid-based	physical pH sensitive	gene delivery mRNA/samRNA	Neurological diseases in vivo rodent models	Safety/pharmacology Pre-GLP toxicity
Researcher: Nicolas Bertrand Institution: Laval University Nanodelivery type Polymer-based Lipid-based Targeting approach Active targeting Application Drug delivery: Soluble molecules; Insoluble molecules Disease model(s) Cancer (In vitro, In vivo xenograft model, Primary cells) Other: Chronic kidney disease (In vivo: rat/mouse) Protocols: Safety/pharmacology (Pre-GLP toxicity)	Laval University	Nicolas Bertrand	Lipid-based Polymer-based	Active targeting	Drug delivery Soluble molecules Insoluble molecules	Cancer Other Chronic kidney disease In vivo Rats and mice In vitro In vivo xenograft model Primary cells	Safety/pharmacology Pre-GLP toxicity
Researcher: Anna Blakney Institution: University of British Columbia Nanodelivery type Lipid-based Polymer-based Targeting approach Physical targeting: pH sensitive; Other (charge) Application Drug delivery: Soluble molecules Gene delivery: mRNA/samRNA Nano-imaging: Fluorescent imaging Disease model(s) Cancer (In vitro; In vivo xenograft model) Infectious diseases: Viral infections; Bacterial infections; BioSafety Level 2; In vitro (cells); In vivo (rodent) Protocols: Safety/pharmacology; Microfluidics	University of British Columbia	Anna Blakney	Lipid-based Polymer-based	Physical targeting pH sensitive Other: charge	Drug delivery Soluble molecules Gene delivery mRNA/samRNA Nano-imaging Fluorescent imaging	Cancer In vitro In vivo xenograft model Infectious diseases Viral infections Bacterial infections BioSafety Level 2 In vitro (cells) In vivo (rodent)	Safety/pharmacology Microfluidics
Researcher: Davide Brambilla Institution: Université de Montréal Nanodelivery type Lipid-based Polymer-based Targeting approach Active targeting: Peptide; Aptamer Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, mRNA/samRNA Disease model(s) Rare diseases (In vitro; In vivo: Rodents) Other: inflammatory diseases (In vitro; In vivo: Rodents) Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics Auxiliary expertise: Non-nano delivery systems; Health Technology Assessment (HTA)/early Health technology Assessment (eHTA)	Université de Montréal2	Davide Brambilla	Lipid-based Polymer-based	Active targeting Peptide Aptamer	Drug delivery Gene delivery Soluble molecules Insoluble molecules DNA mRNA/samRNA	Rare diseases Other Inflammatory diseases In vitro In vivo Rodents	Safety/pharmacology Microfluidics Pre-GLP toxicity		Non-nano delivery systems Health Technology Assessment (HTA)/early Health technology Assessment (eHTA)
Researcher: Warren Chan Institution: University of Toronto Nanodelivery type LIpid-based Polymer-based Inorganic Targeting approach Active targeting: Antibody or antibody fragments; Peptide Physical targeting: Other (looking at the mechanism of targeting) Application Drug delivery: Soluble molecules Gene delivery: siRNA, mRNA/samRNA Disease model(s) Cancer (In vivo xenograft model, In vivo orthotopic model, In vivo PDX model, In vivo syngeneic model, In vivo metastatic model) Auxiliary expertise: We are mostly working on the mechanism of targeted delivery, rather than attempting to target for therapeutic purposes.	University of Toronto	Warren Chan	Lipid-based Polymer-based Inorganic	Active targeting Physical targeting Other Antibody or antibody fragments Peptide	Drug delivery Gene delivery Soluble molecules siRNA mRNA/samRNA	Cancer			We are mostly working on the mechanism of targeted delivery, rather than attempting to target for therapeutic purposes.
Researcher: Devika Chithrani Institution: University of Victoria Nanodelivery type Lipid-based-based Inorganic Targeting approach Active targeting: Peptide Application Other: Use of nanoparticles for improving radiosensitsation Disease model(s) Cancer (In vitro, In vivo xenograft model, In vivo syngeneic model) Protocols: Safety/pharmacology: Pre-GLP toxicity Instrumentation: A magnetic lens system to separate co-cultured cells	University of Victoria	Devika Chithrani	Lipid-based Inorganic	Active targeting Peptide	Other Use of nanoparticles for improving radiosensitsation	Cancer In vitro In vivo xenograft model In vivo syngeneic model	Safety/pharmacology Pre-GLP toxicity	A magnetic lens system to separate co-cultured cells
Researcher: Marco Ciufolini Institution: University of British Columbia (UBC); NanoVation Therapeutics Nanodelivery type Lipid-based Targeting approach Physical targeting: pH sensitive Application Gene delivery: DNA; siRNA; mRNA/samRNA Disease model(s) Cancer Rare diseases Infectious diseases: Viral infections Protocols: Other: synthetic organic chemistry	University of British Columbia; NanoVation Therapeutics	Marco Ciufolini	Lipid-based	Physical targeting pH sensitive	Gene delivery DNA siRNA mRNA/samRNA	Cancer Rare diseases Infectious diseases Viral infections	Other synthetic organic chemistry
Researcher: Michael Doschak Institution: University of Alberta Nanodelivery type Other: Metal oxide nanoparticle contrast agents Targeting approach Active targeting: Small molecule Application Drug delivery: Soluble molecules Peptide/protein delivery Nano-imaging: Theranostics; Fluorescent imaging; Other (Micro-CT and Micro-MRI) Disease model(s) Cancer (In vitro, In vivo metastatic model) Arthritis (In vivo: post-traumatic OA models after ACL-transection and/or medial meniscectomy) Other: osteoporosis (In vitro, In vivo: mouse, rat, rabbit) Protocols: Safety/pharmacology (Pre-GLP toxicity); Other (bone dynamic labels; Quantitative image analysis for bone volume and bone mineral density) Instrumentation: in-vivo micro-CT; Bone electron probe microanalysis (EPMA) Auxiliary expertise: Non-nano delivery systems; Regulatory science	University of Alberta	Michael Doschak	Other Metal oxide nanoparticle contrast agents	Active targeting Small molecule	Drug delivery Peptide/protein delivery Nano-imaging Soluble molecules Theranostics Fluorescent imaging Other Micro-CT and Micro-MRI	Cancer Arthritis Other Osteoporosis In vitro In vivo mouse, rat, rabbit In vitro In vivo metastatic model In vivo post-traumatic OA models after ACL-transection and/or medial meniscectomy	Safety/pharmacology Other Pre-GLP toxicity bone dynamic labels; Quantitative image analysis for bone volume and bone mineral density	in-vivo micro-CT; Bone electron probe microanalysis (EPMA)	Regulatory science Non-nano delivery systems
Researcher: Richard Epand Institution: McMaster University Nanodelivery type LIpid-based Targeting approach Active targeting: Antibody or antibody fragments Application Drug delivery: Insoluble molecules Disease model(s) Cancer (In vitro) Rare diseases (In vitro) Protocols: Safety/pharmacology Instrumentation: Circular dichroism Auxiliary expertise: Regulatory science	McMaster University	Richard Epand	Lipid-based	Active targeting Antibody or antibody fragments	Drug delivery Insoluble molecules	Cancer Rare diseases In vitro In vitro	Safety/pharmacology	Circular dichroism	Regulatory science
Researcher: Joel Finbloom Institution: University of British Columbia Nanodelivery type Polymer-based Other: Peptide self-assembly Targeting approach Physical targeting: pH sensitive; Other (Enzyme activation; Dynamic bioconjugation) Application Drug delivery: Soluble molecules; Insoluble molecules Disease model(s) Infectious diseases: Bacterial infections – BioSafety Level 2, In vitro (cells), In vivo (rodent) Other: GI disorders (IBD) (In vitro, Organoid, In vivo: Colitis mouse model) Auxiliary expertise: Non-nano delivery systems; Other: Bioconjugation chemistry	University of British Columbia	Joel Finbloom	Polymer-based Other Peptide self-assembly	Physical targeting Other pH sensitive Enzyme activation. Dynamic bioconjugation	Drug delivery Soluble molecules Insoluble molecules	Infectious diseases Other Bacterial infections GI disorders (IBD) In vitro Organoid In vivo Colitis mouse model BioSafety Level 2 In vitro (cells) In vivo (rodent)			Non-nano delivery systems Other Bioconjugation chemistry
Researcher: Marianna Foldvari Institution: University of Waterloo Nanodelivery type Lipid-based Other: surfactant and carbon nanomaterials Targeting approach Other: Peptides Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, mRNA/samRNA Peptide/protein delivery Disease model(s) Other: neurodegenerative diseases – In vitro, In vivo: retinal diseases (glaucoma), skin diseases (scleroderma/morphoea) Protocols: Pre-GMP & GMP manufacturing Auxiliary expertise: Non-nano delivery systems	University of Waterloo	Marianna Foldvari	Lipid-based Other surfactant and carbon nanomaterials	Other peptides	Drug delivery Gene delivery Peptide/protein delivery Soluble molecules Insoluble molecules DNA mRNA/samRNA	Other neurodegenerative diseases In vitro In vivo” retinal diseases (glaucoma), skin diseases (scleroderma/morphoea)	Pre-GMP & GMP manufacturing		Non-nano delivery systems
Researcher: Marc-André Fortin Institution: Laval University Nanodelivery type Inorganic Other: hydrogels, nanoparticle-eluting hydrogels Targeting approach Active targeting: Antibody or antibody fragments; Small molecule Application Nano-imaging: Diagnostics; Theranostics; PET; Other (MRI contrast agents, radiosensitization compounds for radio-oncology) Other: MRI-visible inks for bioprinting and tissue engineering applications; radiosensitization compunds for radiooncology Disease model(s) Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model) Diabetes (Organoid) Protocols: Safety/pharmacology (Pre-GLP toxicity); Other: Relaxometry of MRI contrast agents, PET-operated Franz diffusion cells (for measuring diffusion coefficients of NPs across membranes) Instrumentation: Relaxometric analysis of MRI contrast agents, PET biodistribution, 3D printing infrastructure (including bioprinting) Auxiliary expertise: Non-nano delivery systems	Laval University	Marc-André Fortin	Inorganic Other hydrogels, nanoparticle-eluting hydrogels	Active targeting Antibody or antibody fragments Small molecule	Nano-imaging Other Diagnostics Theranostics PET Other MRI-visible inks for bioprinting and tissue engineering applications; radiosensitization compunds for radiooncology MRI contrast agents, radiosensitization compounds for radio-oncology	Cancer Diabetes In vitro Organoid In vivo xenograft model In vivo orthotopic model Organoid	Safety/pharmacology Other Pre-GLP toxicity Relaxometry of MRI contrast agents, PET-operated Franz diffusion cells (for measuring diffusion coefficients of NPs across membranes)	Relaxometric analysis of MRI contrast agents, PET biodistribution, 3D printing infrastructure (including bioprinting)	Non-nano delivery systems
Researcher: Marc A Gauthier Institution: Institut National de la Recherche Scientifique Nanodelivery type Polymer-based Targeting approach Active Targeting: Antibody or antibody fragments; Peptide; Aptamer Physical Targeting: pH sensitive; Temperature sensitive; Other (ROS; Enzymes; Thiol-Disulfide; etc.) Application Drug delivery: Soluble molecules Peptide/protein delivery Disease model(s) Cancer (In vitro, In vivo xenograft model, Primary cells) Other: several diseases (In vitro, In vivo) Auxiliary expertise: Non-nano delivery systems	Institut National de la Recherche Scientifique	Marc A Gauthier	Polymer-based	Active Targeting: Antibody or antibody fragments; Peptide; Aptamer Physical Targeting: pH sensitive; Temperature sensitive; Other (ROS; Enzymes; Thiol-Disulfide; etc.)	Drug delivery: Soluble molecules Peptide/protein delivery	Cancer (In vitro, In vivo xenograft model, Primary cells) Other: several diseases (In vitro, In vivo)			Non-nano delivery systems
Researcher: Azita Haddadi Institution: University of Saskatchewan Nanodelivery type Lipid-based Polymer-based Targeting approach Active targeting: Antibody or antibody fragments; Peptide Physical targeting: temperature sensitive, light sensitive Application Drug delivery: Soluble molecules; Insoluble molecules Peptide/protein delivery Disease model(s) Cancer (In vitro, In vivo xenograft model, Primary cells) Heart failure (In vitro) Infectious diseases: Viral infections – BioSafety Level 2; In vitro (cells), In vivo (rodent), In vivo (larger animals) Auxiliary expertise: Non-nano delivery systems	University of Saskatchewan	Azita Haddadi	Lipid-based Polymer-based	Active targeting: Antibody or antibody fragments; Peptide Physical targeting: temperature sensitive, light sensitive	Drug delivery: Soluble molecules; Insoluble molecules Peptide/protein delivery	Cancer (In vitro, In vivo xenograft model, Primary cells) Heart failure (In vitro) Infectious diseases: Viral infections – BioSafety Level 2; In vitro (cells), In vivo (rodent), In vivo (larger animals)			Non-nano delivery systems
Researcher: Andrew Halayko Institution: University of Manitoba Nanodelivery type Lipid-based Application Drug delivery: Soluble molecules Peptide/protein delivery Disease model(s) Diabetes (In vitro, In vivo: mouse/rat) Infectious diseases: Viral infections (In vitro, In vivo, Biosafety level 3) Other: Inflammatory lung disease – asthma, COPD (In vitro, In vivo: mouse) Instrumentation: Pulmonary function assessing small animals, as well as optical in vivo imaging Auxiliary expertise: Other: We offer animal and cell models in which to test nano-vectors	University of Manitoba	Andrew Halayko	Lipid-based		Drug delivery Peptide/protein delivery Soluble molecules	Diabetes Infectious diseases Other Viral infections Inflammatory lung disease – asthma, COPD In vitro In vivo Mouse In vivo Mouse / rat In vitro In vivo Biosafety level 3		Pulmonary function assessing small animals, as well as optical in vivo imaging	We offer animal and cell models in which to test nano- vectors
Researcher: Robert Hancock Institution: University of British Columbia Nanodelivery type LIpid-based Polymer-based Targeting approach Physical targeting: pH sensitive Application Drug delivery: Soluble molecules Disease model(s) Infectious diseases: Bacterial infections; BioSafety Level 2; In vitro (cells); In vitro (organoids); In vivo (rodent) Other: Inflammation (Organoid; In vivo: skin abscess model; mouse sinusitis model)	University of British Columbia	Robert Hancock	Lipid-based Polymer-based	Physical targeting pH sensitive	Drug delivery Soluble molecules	Infectious diseases Other Bacterial infections Inflammation Organoid In vivo Skin Abscess model; Mouse Sinusitis model BioSafety Level 2 In vitro (cells) In vitro (organoids) In vivo (rodent)
Researcher: Ken Harder Institution: University of British Columbia (UBC) Nanodelivery type Lipid-based Targeting approach Other: 5 or 6 component LNPs for immune cell specific targeting Application Gene delivery: mRNA/samRNA Disease model(s) Cancer (In vitro, In vivo syngeneic model, In vivo metastatic model) Other: Alzheimer’s, obesity and atherosclerosis (In vitro, In vivo; mouse models) Protocols: Other: CyTOF and CITE-seq protein and transcriptomic analysis of LNP targeting Instrumentation: CyTOF Auxiliary expertise: Non-nano delivery systems	University of British Columbia (UBC)	Ken Harder	Lipid-based	Other: 5 or 6 component LNPs for immune cell specific targeting	Gene delivery: mRNA/samRNA	Cancer (In vitro, In vivo syngeneic model, In vivo metastatic model) Other: Alzheimer’s, obesity and atherosclerosis (In vitro, In vivo; mouse models)	Other: CyTOF and CITE-seq protein and transcriptomic analysis of LNP targeting	CyTOF	Non-nano delivery systems
Researcher: Emmanuel Ho Institution: University of Waterloo Nanodelivery type Lipid-based Polymer-based Inorganic Targeting approach Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive; temperature sensitive; light sensitive Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA Peptide/protein delivery Disease model(s) Cancer (In vitro; In vivo xenograft model; In vivo orthotopic model; In vivo metastatic model) Diabetes (In vitro) Rare diseases (In vitro) Infectious diseases: Viral infections; Bacterial infections; BioSafety Level 2; In vitro (cells); In vivo (rodent) Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics Instrumentation: 3D printing, mechanical testing, hot-melt injection molding, microfluidics, microwave sensors Auxiliary expertise: Non-nano delivery systems	University of Waterloo	Emmanuel Ho	Lipid-based Polymer-based Inorganic	Active targeting (e.g., antibodyÂ modification of nanomedicine) Physical targeting (e.g., use of pH sensitiveÂ nanomedicine) Antibody or antibody fragments Peptide Small molecule pH sensitive Temperature sensitive Light sensitive	Drug delivery Gene delivery Peptide/protein delivery Soluble molecules Insoluble molecules DNA siRNA mRNA/samRNA	Cancer Rare diseases Diabetes Infectious diseases Viral infections Bacterial infections In vitro In vivo xenograft model In vivo orthotopic model In vivo metastatic model In vitro In vitro BioSafety Level 2 In vitro (cells) In vivo (rodent)	Safety/pharmacology Microfluidics Pre-GLP toxicity	3D printing, Mechanical testing, hot-melt injection molding, microfluidics, microwave sensors	Non-nano delivery systems
Researcher: Umar Iqbal Institution: National Research Council of Canada Nanodelivery type Lipid-based Targeting approach Active targeting: Antibody or antibody fragments; Peptide Physical targeting: Other (novel lipids and new lipid chemistry) Application Gene delivery: mRNA/samRNA; ASO Disease model(s) Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model, Human) Rare diseases (Human) Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics	National Research Council of Canada	Umar Iqbal	Lipid-based	Active targeting: Antibody or antibody fragments; Peptide Physical targeting: Other (novel lipids and new lipid chemistry)	Gene delivery: mRNA/samRNA; ASO	Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model, Human) Rare diseases (Human)	Safety/pharmacology (Pre-GLP toxicity); Microfluidics
Researcher: Jonathan Irish Institution: Princess Margaret Research Institute Nanodelivery type Lipid-based Targeting approach Active targeting: Antibody or antibody fragments; Small molecule Application Drug delivery: Soluble molecules; Insoluble molecules Nano-imaging: Diagnostics; Theranostics; Fluorescent imaging; PET; SPECT Disease model(s) Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo PDX model, In vivo syngeneic model, In vivo metastatic model, Primary cells, Human) Protocols: Safety/pharmacology (Pre-GLP toxicity, GLP testing); Pre-GMP & GMP manufacturing Auxiliary expertise: Non-nano delivery systems	Princess Margaret Research Institute	Jonathan Irish	Lipid-based	Active targeting Antibody or antibody fragments Small molecule	Drug delivery Soluble molecules Insoluble molecules Nano-imaging Diagnostics Theranostics Fluorescent imaging PET SPECT	Cancer In vitro In vivo xenograft model In vivo orthotopic model In vivo PDX model In vivo syngeneic model In vivo metastatic model Primary cells Human	Safety/pharmacology Pre-GMP & GMP manufacturing Pre-GLP toxicity GLP testing		Non-nano delivery systems
Researcher: Yimei Jia Institution: National Research Council Canada Nanodelivery type Lipid-based Polymer-based Targeting approach Active targeting: Antibody or antibody fragments; Peptide; Small molcule Physical targeting: pH sensitive; temperature sensitive Other Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO Peptide/protein delivery Disease model(s) Cancer (In vitro, Organoid, In vivo syngeneic model, Primary cells) Arthritis (In vitro) Diabetes (In vitro) Infectious diseases: Viral infections; Bacterial infections; BioSafety Level 2; In vitro (cells); In vitro (organoids); In vivo (rodent) Protocols: Safety/pharmacology (Pre-GLP toxicity); Pre-GMP & GMP manufacturing; Microfluidics Instrumentation: nanoassemblr ignite	national research council canada	yimei jia	Lipid-based Polymer-based	Active targeting Physical targeting Other Antibody or antibody fragments Peptide pH sensitive Temperature sensitive	Drug delivery Gene delivery Peptide/protein delivery Soluble molecules Insoluble molecules DNA siRNA mRNA/samRNA ASO	Cancer Arthritis Diabetes Infectious diseases Viral infections Bacterial infections In vitro Organoid In vivo syngeneic model Primary cells In vitro In vitro BioSafety Level 2 In vitro (cells) In vitro (organoids) In vivo (rodent)	Safety/pharmacology Microfluidics Pre-GMP & GMP manufacturing Pre-GLP toxicity	nanoassemblr ignite
Researcher: Jessica Kalra Institution: University of British Columbia (UBC) Nanodelivery type Lipid-based Application Drug delivery: Soluble molecules; Insoluble molecules Disease model(s) Cancer (In vitro, Organoid) Other: Neurological and inflammatory disease (In vitro, Organoid) Protocols: Microfluidics Auxiliary expertise: Other: In vivo modelling and imaging	University of British Columbia (UBC)	Jessica Kalra	Lipid-based		Drug delivery: Soluble molecules; Insoluble molecules	Cancer (In vitro, Organoid) Other: Neurological and inflammatory disease (In vitro, Organoid)	Microfluidics		Other: In vivo modelling and imaging
Researcher: Christian Kastrup Institution: University of British Columbia Nanodelivery type Lipid-based Inorganic Targeting approach Active targeting Physical targeting Other: Lipid and Glyco Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO Disease model(s) Cancer (In vivo metastatic model) Rare diseases (In vivo: rodents and large animals; Human) Infectious diseases – bacterial infections: BioSafety Level 2, In vivo (rodent) Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics; Pre-GMP & GMP manufacturing	University of British Columbia	Christian Kastrup	Lipid-based Inorganic	Active targeting Physical targeting Other Lipid and Glyco	Drug delivery Gene delivery Soluble molecules Insoluble molecules DNA siRNA mRNA/samRNA ASO	Cancer Rare diseases Infectious diseases Bacterial infections In vivo metastatic model In vivo Human Rodents and Large Animals BioSafety Level 2 In vivo (rodent)	Safety/pharmacology Microfluidics Pre-GMP & GMP manufacturing Pre-GLP toxicity
Researcher: Marianna Kulka Institution: Quantum and Nanotechnologies Research Center, University of Alberta Nanodelivery type Lipid-based Polymer-based Inorganic Targeting approach Active targeting: Antibody or antibody fragments; Aptamer Physical targeting: pH sensitive Application Drug delivery: Soluble molecules, insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA Disease model(s) Other: Inflammation (In vitro; human) Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics	Quantum and Nanotechnologies Research Center, University of Alberta	Marianna Kulka	Lipid-based Polymer-based Inorganic	Active targeting Physical targeting Antibody or antibody fragments Aptamer pH sensitive	Drug delivery Gene delivery Soluble molecules Insoluble molecules DNA siRNA mRNA/samRNA	Other inflammation In vitro Human	Safety/pharmacology Microfluidics Pre-GLP toxicity
Researcher: Hagar Labouta Institution: University of Toronto Nanodelivery type Lipid-based Polymer-based Inorganic Targeting approach Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive; Temperature sensitive; Light sensitive Application Drug delivery Gene delivery: siRNA, mRNA/samRNA Disease model(s) Cancer (In vitro, Organoid) Rare diseases (In vitro, Organoid) Other: Pregnancy-associated diseases (In vitro, Organoid) Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics; Other: Organ-on-a-chip Instrumentation: dynamic flow platform for applying shear stress	University of Toronto	Hagar Labouta	Lipid-based Polymer-based Inorganic	Active targeting Physical targeting Antibody or antibody fragments Peptide Small molecule pH sensitive Temperature sensitive Light sensitive	Drug delivery Gene delivery siRNA mRNA/samRNA	Cancer Rare diseases Other Pregnancy-associated diseases In vitro Organoid	Safety/pharmacology Microfluidics Other Pre-GLP toxicity Organ-on-a-chip	dynamic flow platform for applying shear stress
Researcher: Afsaneh Lavasanifar Institution: University of Alberta Nanodelivery type Polymer-based Targeting approach Active targeting: Antibody or antibody fragments; Peptide Application Drug delivery: Insoluble molecules Disease model(s) Cancer (In vitro; In vivo xenograft model; In vivo orthotopic model; In vivo metastatic model) Protocols: Other: Measurement of mucosal permeation and retention of drug delivery systems Instrumentation: Dynamic Mucosal Retention/Permeation tester Auxiliary expertise: Non-nano delivery systems	University of Alberta	Afsaneh Lavasanifar	Polymer-based	Active targeting Antibody or antibody fragments Peptide	Drug delivery Insoluble molecules	Cancer In vitro In vivo xenograft model In vivo orthotopic model In vivo metastatic model	Other Measurement of mucosal permeation and retention of drug delivery systems	Dynamic Mucosal Retention/Permeation tester	Non-nano delivery systems
Researcher: Sabrina Leslie Institution: University of British Columbia Nanodelivery type Lipid-based Targeting approach Physical targeting: pH sensitive; temperature sensitive Application Drug delivery: Insoluble molecules Peptide/protein delivery Nano-imaging: Fluorescent imaging Disease model(s) Cancer (In vitro) Rare diseases (In vitro) Protocols: Microfluidics; Other (Single-molecule and single-particle microscopy) Instrumentation: Convex Lens-induced Confinement (CLiC) Auxiliary expertise: Health Technology Assessment (HTA)/early Health technology Assessment (eHTA)	University of British Columbia	Sabrina Leslie	Lipid-based	Physical targeting pH sensitive Temperature sensitive	Drug delivery Peptide/protein delivery Nano-imaging Insoluble molecules Fluorescent imaging	Cancer Rare diseases In vitro In vitro	Microfluidics Other Single-molecule and single-particle microscopy	Convex Lens-induced Confinement (CLiC)	Health Technology Assessment (HTA)/early Health technology Assessment (eHTA)
Researcher: Alex Leung Institution: Evonik Canada Nanodelivery type Lipid-based Application Drug delivery Gene delivery: siRNA, mRNA/samRNA Protocols: Microfluidics; Pre-GMP & GMP manufacturing	Evonik Canada	Alex Leung	Lipid-based		Drug delivery Gene delivery siRNA mRNA/samRNA		Microfluidics Pre-GMP & GMP manufacturing
Researcher: Sherry Leung Institution: Precision NanoSystems Nanodelivery type Lipid-based Application Gene delivery Protocols: Microfluidics	Precision NanoSystems	Sherry Leung	Lipid-based		Gene therapy		Microfluidics
Researcher: Bowen Li Institution: University of Toronto Nanodelivery type Lipid-based Targeting approach Active targeting: Antibody or antibody fragments; Small molecule Other targeting: Chemistry based targeting (e.g. ,affects protein corona formation by adjusting surface charge) Application Gene delivery: mRNA/samRNA Disease model(s) Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo metastatic model) Rare diseases (In vitro; In vivo: cystic fibrosis) Infectious diseases – Viral infections: BioSafety Level 2; In vitro (cells); In vitro (organoids); In vivo (rodent)	University of Toronto	Bowen Li	Lipid-based	Active targeting Other Antibody or antibody fragments Small molecule Chemistry based targeting (e.g. affects protein corona formation by adjusting surface charge)	Gene delivery mRNA/samRNA	Cancer Rare diseases Infectious diseases Viral infections In vitro In vivo xenograft model In vivo orthotopic model In vivo metastatic model In vitro In vivo Cystic fibrosis BioSafety Level 2 In vitro (cells) In vitro (organoids) In vivo (rodent)
Researcher: Shyh-Dar Li Institution: University of British Columbia (UBC) Nanodelivery type Lipid-based Polymer-based Targeting approach Other: EPR effect, protein corona Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO Peptide/protein delivery Disease model(s) Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Rare diseases (In vivo: cancer, genetic diseases) Diabetes (In vivo: STZ induced) Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics	University of British Columbia (UBC)	Shyh-Dar Li	Lipid-based Polymer-based	Other: EPR effect, protein corona	Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO Peptide/protein delivery	Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Rare diseases (In vivo: cancer, genetic diseases) Diabetes (In vivo: STZ induced)	Safety/pharmacology (Pre-GLP toxicity) Microfluidics
Researcher: Raimar Loebenberg Institution: University of Alberta Nanodelivery type Lipid-based Polymer-based Targeting approach Physical targeting: Other (lymphatic) Application Drug delivery: Soluble molecules; Insoluble molecules Peptide/protein delivery Disease model(s) Cancer (In vitro) Infectious diseases: bacterial infections – BioSafety Level 2; In vitro (cells) Protocols: Pre-GMP & GMP manufacturing Instrumentation: clean room Auxiliary expertise: Regulatory science	University of Alberta	Raimar Loebenberg	Lipid-based Polymer-based	Physical targeting Other lymphatic	Drug delivery Peptide/protein delivery Soluble molecules, Insoluble molecules	Cancer Infectious diseases Bacterial infections In vitro BioSafety Level 2 In vitro (cells)	Pre-GMP & GMP manufacturing	clean room	Regulatory science
Researcher: Simon Matoori Institution: Université de Montréal Nanodelivery type Lipid-based Polymer-based Disease model(s) Diabetes (In vivo: db/db mice, STZ mice) Auxiliary expertise: Non-nano delivery systems	Université de Montréal	Simon Matoori	Lipid-based Polymer-based			Diabetes In vivo db/db mice, STZ mice			Non-nano delivery systems
Researcher: Naomi Matsuura Institution: University of Toronto Nanodelivery type Lipid-based Targeting approach Other: Image-guided targeting (focusing energy from outside the patient for local uptake of therapeutics) Application Drug delivery: Soluble molecules; Insoluble molecules Nano-imaging: Diagnostics; Theranostics; Fluorescent imaging; PET; Other (ultrasound, CT) Disease model(s) Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model) Protocols: Microfluidics; Other: Ultrasound-guided focused ultrasound (FUS) delivery Instrumentation: FUS, Ultrasound, Raman microscope, bioprinter	University of Toronto	Naomi Matsuura	Lipid-based	Other Image-guided targeting (focusing energy from outside the patient for local uptake of therapeutics)	Drug delivery Nano-imaging Soluble molecules Insoluble molecules Diagnostics Theranostics FluorescentÂ imaging PET Other ultrasound, CT	Cancer In vitro In vivo xenograft model In vivo orthotopic model In vivo syngeneic model	Microfluidics Other Ultrasound-guided focused ultrasound (FUS) delivery	FUS, Ultrasound, Raman microscope, bioprinter
Researcher: Michel Meunier Institution: Polytechnique Montreal Nanodelivery type Lipid-based Inorganic Targeting approach Active targeting: Antibody or antibody fragments Physical targeting: Light sensitive Application Drug delivery: Soluble molecules Gene delivery: siRNA, mRNA/samRNA Disease model(s) Cancer (In vitro) Other: ophthalmology (In vitro)	Polytechnique Montreal	Michel Meunier	Lipid-based Inorganic	Active targeting: Antibody or antibody fragments Physical targeting: Light sensitive	Drug delivery: Soluble molecules Gene delivery: siRNA, mRNA/samRNA	Cancer (In vitro) Other: ophthalmology (In vitro)
Researcher: Robert Molday Institution: University of British Columbia Nanodelivery type Lipid-based Targeting approach Active targeting: Antibody or antibody fragments Physical targeting: pH sensitive Application Gene delivery: DNA, mRNA/samRNA Peptide/protein delivery Disease model(s) Rare diseases (In vitro, Organoid, In vivo, mouse)	University of British Columbia	Robert Molday	Lipid-based	Active targeting Antibody or antibody fragments Physical targeting pH sensitive	Gene delivery Peptide/protein delivery DNA mRNA/samRNA	Rare diseases In vitro Organoid In vivo mouse
Researcher: Ignace Moya Institution: Krembil Institute Nanodelivery type Polymer-based Targeting approach Active targeting: Peptide Application Drug delivery: Soluble molecules Peptide/protein delivery Disease model(s) Cancer (In vitro, Organoid, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Other: stroke & COVID (In vitro, Human) Protocols: Safety/pharmacology (GLP testing); Pre-GMP & GMP manufacturing Instrumentation: HPLC (analytical and semiprep), peptide synthesizer, lyophilizer	Krembil Institute	Ignace Moya	Polymer-based	Active targeting Peptide	Drug delivery Peptide/protein delivery Soluble molecules	Other stroke, and COVID In vitro Human	Safety/pharmacology Pre-GMP & GMP manufacturing GLP testing	HPLC (analytical and semiprep), peptide synthesizer, lyophilizer
Researcher: Clement Mugabe Institution: Evonik Nanodelivery type Lipid-based Polymer-based Targeting approach Other: Passive targeting Application Drug Delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO Peptide/protein delivery Disease model(s) Other: We work with many partners who have access to many disease models (In vitro) Protocols: Pre-GMP & GMP manufacturing Unique instrumentation: PAT to monitor downstream purification process for LNP formulations Auxiliary expertise: Other: Evonik Vancouver Laboratories is a global CDMO for lipid nanoparticle and liposome-based formulations. We provide end-to-end services for lipid nanoparticle formulations including formulation and process development, scale up and clinical manufacturing of lipid based drug products. We offer a highly purified plant-derived cholesterol (PhytoChol) in GMP grade. We can also develop and manufacture custom-made lipids and polymers to support your clinical development.	Evonik	Clement Mugabe	Lipid-based Polymer-based	Other Passive targeting	Drug delivery Gene delivery Peptide/protein delivery Soluble molecules Insoluble molecules DNA siRNA mRNA/samRNA ASO	Other We work with many partners who have access to many disease models In vitro	Pre-GMP & GMP manufacturing	PAT to monitor downstream purification process for LNP formulations	Other Evonik Vancouver Laboratories is a global CDMO for lipid nanoparticle and liposome-based formulations. We provide end-to-end services for lipid nanoparticle formulations including formulation and process development, scale up and clinical manufacturing of lipid based drug products. We offer a highly purified plant-derived cholesterol (PhytoChol) in GMP grade. We can also develop and manufacture custom-made lipids and polymers to support your clinical development.
Researcher: Keith Pardee Institution: University of Toronto Nanodelivery type Polymer-based Lipid-based Targeting approach Active targeting: Antibody or antibody fragments; Peptide; Aptamer Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: mRNA/samRNA Peptide/protein delivery Disease model(s) Cancer (In vitro) Infectious diseases: viral infections – BioSafety Level 2, In vitro (cells) Protocols: Microfluidics Instrumentation: focus on molecular interactions with nanomaterials (bioconjugation) Auxiliary expertise: Non-nano delivery systems	University of Toronto	Keith Pardee	Lipid-based Polymer-based	Active targeting Antibody or antibody fragments Peptide Aptamer	Gene delivery Peptide/protein delivery mRNA/samRNA	Cancer Infectious diseases Viral infections In vitro BioSafety Level 2 In vitro (cells)	Microfluidics	focus on molecular interactions with nanomaterials (bioconjugation)	Non-nano delivery systems
Researcher: Arghya Paul Institution: University of Western Ontario Nanodelivery type Lipid-based Polymer-based Inorganic Application Drug delivery: Soluble molecules, Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA Disease model(s) Cancer: In vitro, Organoid, In vivo xenograft model Diabetes: In vitro, In vivo Other: Liver Disease Protocols: Microfluidics	University of Western Ontario	Arghya Paul	Lipid-based Polymer-based Inorganic		Drug delivery Gene delivery Soluble molecules Insoluble molecules DNA siRNA mRNA/samRNA	Cancer Diabetes Other liver disease In vitro Organoid In vivo xenograft model	Microfluidics
Researcher: Raymond Reilly Institution: University of Toronto Nanodelivery type Inorganic Targeting approach Other: Local intratumoural infusion or implantation of gold nanoparticles Application Other: Radioisotope delivery Disease model(s) Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo PDX model, In vivo syngeneic model, Human) Protocols: Safety/pharmacology (Pre-GLP toxicity); Pre-GMP & GMP manufacturing Instrumentation: Radioisotope measurement and small animal imaging systems (SPECT and PET) Auxiliary expertise: Regulatory science	University of Toronto	Raymond Reilly	Inorganic	Other: Local intratumoural infusion or implantation of gold nanoparticles	Other: Radioisotope delivery	Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo PDX model In vivo syngeneic model, Human)	Safety/pharmacology (Pre-GLP toxicity); Pre-GMP & GMP manufacturing	Radioisotope measurement and small animal imaging systems (SPECT and PET)	Regulatory science
Researcher: Colin Ross Institution: University of British Columbia Nanodelivery type Polymer-based Lipid-based Other: AAV Targeting approach Active targeting Application Gene delivery: DNA, mRNA/samRNA Disease model(s) rare diseases (In vitro, In vivo) Protocols: Safety/pharmacology	University of British Columbia	Colin Ross	Lipid-based Polymer-based Other AAV	Active targeting	Gene delivery DNA mRNA/samRNA	Rare diseases In vitro In vivo	Safety/pharmacology
Researcher: Manish Sadarangani Institution: University of British Columbia (UBC) Nanodelivery type Other: bacterial outer membrane vesicles Targeting approach Active targeting: Antibody or antibody fragments Application Other: vaccine delivery Disease model(s) Infectious diseases (Bacterial infections; In vitro [cells], In vivo [rodent]; BioSafety Level 2) Auxiliary expertise: Regulatory science	University of British Columbia (UBC)	Manish Sadarangani	Other: bacterial outer membrane vesicles	Active targeting: Antibody or antibody fragments	Other: vaccine delivery	Infectious diseases (Bacterial infections; In vitro [cells], In vivo [rodent]; BioSafety Level 2)			Regulatory science
Researcher: Michael Serpe Institution: University of Alberta Nanodelivery type Polymer-based Targeting approach Physical targeting: pH sensitive; Temperature sensitive; Light sensitive; Other (electric field, mechanical force) Application Drug delivery: Soluble molecules; Insoluble molecules Disease model(s) Cancer (Human) Other: General novel delivery system development (Human) Protocols: Other: Codelivery of multiple molecules to a system, nanogel/hydrogel composites for fine tuning of drug delivery rate Instrumentation: Multiangle, multi wavelength imaging ellipsometer, quartz crystal microbalance, contact angle goniometer, surface plasmon resonance Auxiliary expertise: Non-nano delivery systems	University of Alberta	Michael Serpe	Polymer-based	Physical targeting pH sensitive Temperature sensitive Light sensitive Other electric field, mechanical force	Drug delivery Soluble molecules Insoluble molecules	Cancer Other General novel delivery system development Human Human	Other Codelivery of multiple molecules to a system, nanogel/hydrogel composites for fine tuning of drug delivery rate	Multiangle, multi wavelength imaging ellipsometer, quartz crystal microbalance, contact angle goniometer, surface plasmon resonance	Non-nano delivery systems
Researcher: Elizabeth Simpson Institution: University of British Columbia Nanodelivery type Lipid-based Application Gene delivery: DNA Disease model(s) Rare diseases: Aniridia (a form of congenital blindness) (In vivo)	University of British Columbia	Elizabeth Simpson	Gene delivery DNA		Rare diseases In vivo Aniridia a congenital blindness
Researcher: Ruby Sullan Institution: University of Toronto Scarborough Nanodelivery type Polymer-based Targeting approach Active targeting: Peptide Application Drug delivery: Soluble molecules Disease model(s) Infectious diseases – Bacterial infections: BioSafety Level 2; In vitro (cells) Instrumentation: Atomic force microscope (AFM)	University of Toronto Scarborough	Ruby Sullan	Polymer-based	Active targeting Peptide	Drug delivery Soluble molecules	Infectious diseases Bacterial infections BioSafety Level 2 In vitro (cells)		Atomic force microscope (AFM)
Researcher: Aneesh Thakur Institution: Vaccine and Infectious Disease Organization, University of Saskatchewan Nanodelivery type Polymer-based Lipid-based Targeting approach Other Application Gene delivery: mRNA/samRNA Nano-imaging: Fluorescent imaging/li> Disease model(s) Infectious diseases: Viral infections, Bacterial infections – BioSafety Level 2, BioSafety Level 3, In vitro (cells), In vivo (rodent), In vivo (larger animals) Protocols: Microfluidics; Other: Immune responses	University of Saskatchewan (Vaccine and Infectious Disease Organization)	Aneesh Thakur	Lipid-based Polymer-based	Other	Gene delivery mRNA/samRNA Nano-imaging Fluorescent imaging	Infectious diseases Viral infections Bacterial infections BioSafety Level 2 BioSafety Level 3 In vitro (cells) In vivo (rodent) In vivo (larger animals)	Microfluidics Other Immune responses
Researcher: Gilbert Walker Institution: University of Toronto Nanodelivery type Lipid-based Polymer-based Targeting approach Active targeting: Antibody or antibody fragments; Small molecule Physical targeting: pH sensitive Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: siRNA, ASO Nano-imaging: Diagnostics Disease model(s) Cancer (In vitro) Infectious diseases (Viral infections; Bacterial infections; BioSafety Level 2; In vitro [cells], In vivo [rodent]) Protocols: Microfluidics Instrumentation: high resolution mechanical and IR imaging	University of Toronto	Gilbert Walker	Lipid-based Polymer-based	Active targeting: Antibody or antibody fragments; Small molecule Physical targeting: pH sensitive	Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: siRNA, ASO Nano-imaging: Diagnostics	Cancer (In vitro) Infectious diseases (Viral infections; Bacterial infections; BioSafety Level 2; In vitro [cells], In vivo [rodent])	Microfluidics	high resolution mechanical and IR imaging
Researcher: Ellen Wasan Institution: University of Saskatchewan Nanodelivery type Polymer-based Lipid-based Targeting approach Physical targeting: pH sensitive Application Drug delivery: Soluble molecules; Insoluble molecules Peptide/protein delivery Disease model(s) Infectious diseases: Viral infections, Bacterial infections Protocols: Microfluidics Instrumentation: access to Canadian Light Source Synchrotron, Malvern Nanosizer Auxiliary expertise: Non-nano delivery systems	University of Saskatchewan	Ellen Wasan	Lipid-based Polymer-based	Physical targeting pH sensitive	Drug delivery Peptide/protein delivery Soluble molecules Insoluble molecules	Infectious diseases Viral infections Bacterial infections	Microfluidics	access to Canadian Light Source Synchrotron, Malvern Nanosizer	Non-nano delivery systems
Researcher: Kishor Wasan Institution: University of British Columbia Nanodelivery type LIpid-based Other: Lipid and Lipoprotein Metabolism as it is related to Drug Delivery Targeting approach Active targeting: Peptide; Small molecule Physical targeting: Other (Lipoprotein Drug Delivery) Application Drug delivery: Soluble molecules; Insoluble molecules Peptide/protein delivery Disease model(s) Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, Human) Infectious diseases: Viral infections, Bacterial infections: BioSafety Level 2, In vitro (cells), In vitro (organoids), In vivo (rodent) Other: Neglected Tropical Diseases- parasitic diseases and fungal diseases (In vivo: Antifungal models, In vitro) Protocols: Safety/pharmacology (Pre-GLP toxicity) Auxiliary expertise: Non-nano delivery systems; Other: Pharmacokinetics and ADME	University of British Columbia	Kishor Wasan	Lipid-based Other Lipid and Lipoprotein Metabolism as it is related to Drug Delivery	Active targeting (e.g., antibodyÂ modification of nanomedicine) Other Small molecule Lipoprotein Drug Delivery	Drug delivery Soluble molecules Insoluble molecules	Cancer Infectious diseases Other Viral infections Bacterial infections Neglected Tropical Diseases- parasitic diseases and fungal diseases In vitro In vivo Antifungal models. In vitro In vivo xenograft model In vivo orthotopic model Human BioSafety Level 2 In vitro (cells) In vitro (organoids) In vivo (rodent)	Safety/pharmacology Pre-GLP toxicity		Non-nano delivery systems Other Pharmacokinetics and ADME
Researcher: David Wishart Institution: University of Alberta Nanodelivery type Lipid-based Inorganic Targeting approach Active targeting: Antibody or antibody fragments Application Peptide/protein delivery Other: assays Disease model(s) Cancer (human) Infectious diseases: Viral infections, Bacterial infections – BioSafety Level 2, In vitro (cells), In vivo (larger animals) Protocols: Microfluidics Unique instrumentation: LC-MS, GC-MS, ICP-MS, NMR Auxiliary expertise: Regulatory science; Marketing expertise; Health Technology Assessment (HTA)/early Health technology Assessment (eHTA)	University of Alberta	David Wishart	Lipid-based Inorganic	Active targeting Antibody or antibody fragments	Peptide/protein delivery Other: assays	Cancer Infectious diseases Viral infections Bacterial infections Human BioSafety Level 2 In vitro (cells) In vivo (larger animals)	Microfluidics	LC-MS, GC-MS, ICP-MS, NMR	Regulatory science Marketing expertise Health Technology Assessment (HTA)/early Health technology Assessment (eHTA)
Researcher: Xiao Yu (Shirley) Wu Institution: University of Toronto Nanodelivery type Polymer-based Other: Polymer-lipid hybrid, polymer-lipid-inorganic based Targeting approach Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive; Other (oxidative stress, disease state biomarkers) Application Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO Peptide/protein delivery Nano-imaging: Diagnostics; Theranostics; Fluorescent imaging; Other (MRI) Disease model(s) Cancer (In vitro, Organoid, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Diabetes (In vitro, In vivo: diabetic rats/mice) Other: neurodegenerative diseases (In vitro, Organoid, In vivo: Alzheimer’s mice, lung injury models) Protocols: Safety/pharmacology Auxiliary expertise: Non-nano delivery systems	University of Toronto	Xiao Yu (Shirley) Wu	Polymer-based Other: Polymer-lipid hybrid, polymer-lipid-inorganic based	Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive; Other (oxidative stress, disease state biomarkers)	Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: DNA, siRNA, mRNA/samRNA, ASO< Peptide/protein delivery Nano-imaging: Diagnostics; Theranostics; Fluorescent imaging; Other (MRI)	Cancer (In vitro, Organoid, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) Diabetes (In vitro, In vivo: diabetic rats/mice) Other: neurodegenerative diseases (In vitro, Organoid, In vivo: Alzheimer’s mice, lung injury models)	Safety/pharmacology		Non-nano delivery systems
Researcher: Shan Zou Institution: National Research Council Canada Nanodelivery type Lipid-based Other: Graphane oxide and boron nitride nanotubes Targeting approach Physical targeting: pH sensitive Application Gene delivery: DNA, siRNA Disease model(s) Cancer (In vitro, Organoid) Protocols: Safety/pharmacology (Pre-GLP toxicity) Instrumentation: CARS	National Research Council Canada	Shan Zou	Lipid-based Other Graphane oxide and boron nitride nanotubes	Physical targeting pH sensitive	Gene delivery DNA siRNA	Cancer In vitro Organoid	Safety/pharmacology Pre-GLP toxicity	CARS